Resistance to Thyroid Hormone Beta (RTH-beta)
Resistance to Thyroid Hormone Beta (RTH-beta)
Understanding RTH-beta
Resistance to Thyroid Hormone Beta (RTH-beta) is a rare endocrine disorder caused by pathogenic variants in the thyroid hormone receptor beta (THRB) gene.
The condition is characterized by reduced responsiveness of target tissues to thyroid hormones, resulting in altered regulation of the hypothalamic-pituitary-thyroid (HPT) axis and disrupted thyroid hormone signaling.
Because thyroid hormone responsiveness may vary between tissues and individuals, the clinical presentation of RTH-beta can be highly heterogeneous.
Clinical Characteristics
Typical biochemical findings may include:
- Elevated circulating thyroid hormone levels (T3 and T4)
- Non-suppressed or inappropriately normal thyroid-stimulating hormone (TSH)
Clinical manifestations may vary and can include:
- Cardiovascular abnormalities
- Goiter
- Low body weight
- Neurocognitive symptoms
- Signs and symptoms of Thyrotoxicosis
The severity and presentation of symptoms may differ considerably between individuals.
RTH-beta and MCT8 Deficiency
Although both conditions affect thyroid hormone signaling, RTH-beta and MCT8 deficiency are distinct disorders with different genetic causes, disease mechanisms and clinical characteristics.
RTH-beta is caused by pathogenic variants in the THRB gene, resulting in altered responsiveness to thyroid hormones at the receptor level.
MCT8 deficiency is caused by pathogenic variants in the SLC16A2 gene and results from impaired transport of thyroid hormones into specific cells and tissues.
As a result, the two disorders have different underlying pathophysiology and clinical management considerations.
Scientific Interest in RTH-beta
Advances in thyroid hormone biology continue to improve understanding of rare endocrine disorders, including both RTH-beta and MCT8 deficiency.
Research into thyroid hormone signaling pathways has contributed significantly to understanding disease mechanisms and may help inform future therapeutic strategies for patients affected by rare thyroid hormone disorders.
Egetis has longstanding expertise in thyroid hormone biology and rare thyroid hormone-related diseases and remains committed to advancing scientific understanding in this field.
Orphan Drug Designation
Tiratricol has received Orphan Drug Designation in both the United States and the European Union for the treatment of Resistance to Thyroid Hormone Beta (RTH-beta).
Orphan Drug Designation is intended to support the development of therapies for rare diseases and does not constitute marketing authorization or approval.
Medical Information
Healthcare professionals seeking additional scientific or medical information regarding RTH-beta, thyroid hormone biology or Egetis research activities may contact the Egetis Medical Information team.
For Healthcare Professionals Only
This page provides scientific and educational information regarding Resistance to Thyroid Hormone Beta (RTH-beta). The information presented is intended for healthcare professionals and should not be considered treatment advice or a recommendation for the use of any medicinal product.
Clinical Trials
Clinical trials are essential to evaluate the safety and effectiveness of therapies in a structured and carefully monitored way
Explore